Kala Pharmaceuticals Inc (NQ: KALA )

8.930 USD -0.080 (-0.89%)

Official Closing Price Updated: 7:44 PM EST, Feb 24, 2021 Add to My Watchlist

Price and Volume

Volume	2,160,030
Open	9.100
Bid (Size)	8.960 (6)
Ask (Size)	9.140 (5)
Prev. Close	9.010
Today's Range	8.720 - 9.140
52wk Range	5.040 - 14.68
Shares Outstanding	24,562,400
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

February 18, 2021

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 17, 2021

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in...

Performance

YTD	+30.17%	+30.17%
1 Month	+25.77%	+25.77%
3 Month	+22.33%	+22.33%
6 Month	-1.76%	-1.76%
1 Year	+45.92%	+45.92%

More News

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

February 16, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

January 20, 2021

Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

January 07, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January

January 04, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

December 18, 2020

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

November 18, 2020

Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease

November 16, 2020

Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference

November 11, 2020

Kala Pharmaceuticals (KALA) Shares Cross Above 200 DMA

February 04, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.